Verastem Total Assets 2011-2021 | VSTM

Verastem total assets from 2011 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Verastem Annual Total Assets
(Millions of US $)
2020 $154
2019 $145
2018 $277
2017 $90
2016 $84
2015 $113
2014 $99
2013 $125
2012 $93
2011 $59
2010 $4
Verastem Quarterly Total Assets
(Millions of US $)
2021-09-30 $112
2021-06-30 $124
2021-03-31 $137
2020-12-31 $154
2020-09-30 $218
2020-06-30 $199
2020-03-31 $208
2019-12-31 $145
2019-09-30 $193
2019-06-30 $219
2019-03-31 $243
2018-12-31 $277
2018-09-30 $183
2018-06-30 $173
2018-03-31 $68
2017-12-31 $90
2017-09-30 $63
2017-06-30 $62
2017-03-31 $76
2016-12-31 $84
2016-09-30 $89
2016-06-30 $95
2016-03-31 $103
2015-12-31 $113
2015-09-30 $124
2015-06-30 $136
2015-03-31 $142
2014-12-31 $99
2014-09-30 $98
2014-06-30 $107
2014-03-31 $116
2013-12-31 $125
2013-09-30 $132
2013-06-30 $80
2013-03-31 $86
2012-12-31 $93
2012-09-30 $99
2012-06-30 $106
2012-03-31 $111
2011-12-31 $59
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.474B $0.089B
Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $122.991B 7.77
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.439B 21.07
Biohaven Pharmaceutical Holding (BHVN) United States $7.159B 0.00
Arcus Biosciences (RCUS) United States $3.161B 0.00
Emergent Biosolutions (EBS) United States $2.298B 8.26
ADC Therapeutics SA (ADCT) Switzerland $1.545B 0.00
Myovant Sciences (MYOV) United Kingdom $1.443B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.348B 0.00
SQZ Biotechnologies (SQZ) United States $0.329B 0.00
Enzo Biochem (ENZ) United States $0.163B 16.00